 SOUTH SAN FRANCISCO, Calif., May 19, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer will discuss progress on its AlloCAR T platform during todays virtual CD19 Forum. The Forum will include results from Phase 1 ALPHA ALLO-501 and ALPHA2 ALLO-501A trials in relapsedrefractory non-Hodgkin lymphoma NHL, developed in collaboration with Servier, as well as safety, pharmacokinetic PK and pharmacodynamic PD data from ALLO-647. ALLO-647 is part of the Companys differentiated lymphodepletion regimen. The Forum will also discuss the Companys approach for optimizing the unique benefits of its allogeneic CAR T therapy platform and the potential role of AlloCAR T therapy in NHL based upon views from clinical trial investigators and early market research. 